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Abstract The effect of the linoleic acid metabolite 13-hy- 
droxyoetadeeadienoie acid (13-HODE) on degranulation of 
human polymorphonuclear ieukocytes (PMNs) was investigated 
by measuring the expression of CDl lb  and CD67 on the plasma 
membrane. 13-HODE (5 pM) by itself induced degranulation of 
PMNs, but to a lesser extent as compared to PAF and fMLP. 
In addition, 13-HODE was found to inhibit the PAF-indueed 
degrannlation whereas an additive effect on the fMLP-induced 
PMNs degranulation was observed. These results indicate that 
13-HODE can play a modulatory role in degranulation of PMNs. 
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1. Introduction 
Polymorphonuclear leukocytes (PMNs) are recruited to sites 
of inflammation i response to chemotactic stimuli, such as 
platelet-activating factor (PAF) and formyl-methionyl-leucyl- 
phenylalanine (fMLP). Subsequently, phagocytosis, produc- 
tion of reactive oxygen species and degranulation may occur. 
PMN degranulation is characterized by release of hydrolytic 
and proteolytic enzymes and by expression of receptors and 
proteins on the plasma membrane, originating from the mem- 
brane of granules and intracellular vesicles [1,2]. Several gran- 
ule types exist in PMNs, which can be discriminated on the 
basis of their content and membrane markers. Degranulation 
of tertiary granules i characterized byrelease of gelatinase and 
upregulation of the heterodimeric glycoprotein CD1 lb/CD18 
(CR3) on the plasma membrane [3,4]. The secretory vesicles 
contain cytochrome b558 and CD11 b/CD 18 [5]. Release of vita- 
min B~2-binding protein and lactoferrin from specific granules 
coincides with enhanced expression of the glycosyl phosphati- 
dylinositol-linked membrane protein CD67 in addition to 
CDI lb/CD18 on the plasma membrane [6-8]. The azurophilic 
granules are recognized by their content of myeloperoxidase, 
lysozyme and the membrane protein CD63 [6]. The different 
granule types exhibit different release kinetics, e.g. the secretory 
vesicles are readily mobilized compared to azurophilic granules 
[9,101. 
Control of degranulation is important o assure that the 
PMN is activated only at the right place and time and to the 
proper extent. Arachidonic acid metabolites, which are pro- 
duced by several cell types involved in the inflammatory proc- 
ess, e.g. PMNs and macrophages, modulate degranulation. The 
5-1ipoxygenase metabolites leukotriene B4 (LTB4) and 5-oxo- 
eicosatetraenoic acid (5-Oxo-ETE) induce PMN degranulation. 
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5-Oxo-ETE and 5-hydroxy-eicosatetraenoic acid (5-HETE) po- 
tentiate the PAF-induced egranulation [11,12]. In contrast, he 
15-1ipoxygenase metabolite of arachidonic acid, 15-hydroxy- 
eicosatetraenoic a id (15-HETE), has been demonstrated to
inhibit the fMLP- and PAF-induced degranulation of 
PMNs [13]. 
Beside metabolism of arachidonic acid, inflammatory cells 
such as PMNs and macrophages convert linoleic acid, whereby 
9- and 13-hydroxyoctadecadienoic acid (9- and 13-HODE) are 
produced [14-16]. 9- and 13-HODE have been shown to inter- 
fere with reactive oxygen species released by guinea pig pulmo- 
nary macrophages and posess chemotactic activity towards 
PMNs [17,18]. Chemoattractants, such as I'M LP and PAF, also 
induce PMN degranulation. Because nothing is known about 
13-HODE in this respect, we studied the effect of 13-HODE on 
degranulation of PMNs by measuring the expression of the 
granule membrane markers CD67 and CDI lb on the plasma 
membrane. 
2. Materials and methods 
2.1. MateriaLs 
PAF, fMLR linoleic acid, bovine serum albumin (BSA; fraction V) 
and lipoxidase I (type IV) were purchased from Sigma Chemical Co, 
St. Louis, USA. Percoll was obtained from Pharmacia Fine Chemicals 
AB, Uppsala, Sweden. Hespan (6% hydroxyethyl starch in 0.9% NaC1. 
sterile) was from Fresenius AG, Bad Homburg, Germany. 
2.2. Antibodies 
The monoclonal antibody (MoAb) B13.9 (lgG~) [7], directed to 
CD67, was purchased from the Central Laboratory of the Dutch Red 
Cross Blood Transfusion Service, Amsterdam, The Netherlands. Anti- 
CDI lb MoAb (lgG~) and the fluorescein sothiocyanate-labeled goat
anti-mouse MoAb (GamFITC) were obtained from Becton Dickinson. 
San Jose, USA. The antibodies were diluted in phosphate-buffered 
saline (PBS) containing 2% (w/v) BSA and 0.1)2% (w/v) sodium azide. 
2.3. Preparation of 13-HODE 
13-HODE was biochemically prepared according to Garssen et al. 
[19]. Briefly, linoleic acid (600 pM) was incubated at 4°C with lipoxi- 
dase I (20,000 U/100 ml) in 0.1 M borate buffer, pH 9.11. 13-HPODE 
production was measured atintervals in a spectrophotometer (20(I 28t) 
nm). The incubation was terminated by acidification topH 4 with HCI. 
13-HPODE was separated from non-metabolized linoleic acid by ad- 
sorption on a TLC-plate and subsequent development i  hexane-di- 
ethylether-acetic acid (70:30 : 0.5). 13-HPODE was eluted from the silica 
with diethyletfier. Subsequently, 13-HPODE was reduced with sodium 
borohydrate. The purity of 13-HODE thus obtained was measured by 
reversed phase HPLC [20] and was lbund to be 95% (3% 9-HODE: 2% 
13-HPODE). 13-HODE was stored in methanol at -80°C. 
2.4. Isolation oJ human PMN.s 
Human PMNs were obtained from blood of normal healthy volun- 
teers (Bloodbank, Red Cross Foundation, Utrecht, The Netherlands) 
anticoagulated bymixing with trisodium citrate-glucose (10: 1: v/v). 
Erythrocytes were removed by addition of Hespan (11 : 3; v/v), mixing 
and subsequent centrifugation f r20 rain at 100 × ,e. The resultant leuko- 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(95)00773-3 
302 M.J. van de Velde et aL/FEBS Letters 369 (1995) 301-304 
cyte-rich supernatant was removed and washed twice with PBS for 
5 min at 400 x g. Then the cell suspension was layered over a discontinuous 
density gradient of Percoll. The required ensities of Percoll (56% (v/v), 
67% (v/v)) were obtained by mixing isoosmotic Percoll and 0.9% NaCI. 
Following centrifugation for 20 min at 1000 x g, the PMNs banded at the 
interface between the two densities of Percoll. The PMN band was 
carefully removed and washed with buffer containing 20 mM Hepes, 
5 mM KCI, 145 mM naCl, 1.3 mM CaCI> 1 mM MgSO4, 2.1 mM 
NaHCO3, 5 mM glucose (pH 7.4). Finally, PMNs were resuspended in 
buffer to yield a concentration f 5 x 10 6 cells/ml. This PMN prepara- 
tion contained >95% PMNs, with a viability of >99% (assessed by 
Trypan Blue exclusion). 
2.5. Analysis of degranulation markers 
Purified PMNs (5 x 105/ml) were prewarmed for 15 min in a shaking 
waterbath at 37°C and subsequently incubated with the compounds 
13-HODE (5 × 10 -6 M) for 10 min and PAF (100 nM) or fMLP (100 
nM) for 5 rain. The effect of 13-HODE on the PAF- and fMLP-induced 
degranulation was studied by preincubation with 13-HODE for 5 min 
and subsequent s imulation with PAF or fMLP for 5 min. The PMNs 
were centrifuged (1000 x g, 2 min, 4°C), washed with ice-cold PBS/2% 
(w/v) BSA/0.02% (w/v) azide (washing buffer), and incubated with the 
MoAb anti-CD67 or anti-CD1 lb for 30 min at 4°C. Thereafter, PMNs 
were washed three times with washing buffer and incubated with 
GamFITC for 30 min at 4°C. Subsequently, the PMNs were washed 
three times with washing buffer and analyzed by flow cytometry 
(FACScan: Becton Dickinson). 
2.6. Data Analysis" 
Results are expressed as mean fluorescence intensity (MFI) + S.E.M. 
The difference between two MFI values was expressed as delta MFI, 
i.e., MFI of stimulated cells minus MFI of cells under basal conditions. 
Paired Student's t test was used to evaluate statistical significance of the 
data; P < 0.05 was considered significant. 
3. Results 
When PMNs were incubated for 10 min with 5/aM 13-HODE 
a significant increase of the CD1 lb expression with 45 + 12% 
was observed. In addition, the expression of CD67 was upreg- 
ulated with the same extent by 13-HODE (Fig. 1, Table 1). 
As shown in Table 1, st imulation of PMNs with PAF (100 
nM) or fMLP (100 nM) also increased the expression o fCD1 lb 
and CD67 on the plasma membrane.  Both degranulat ion mark- 
ers were upregulated to a greater extent after st imulation with 
PAF or fMLP than with 13-HODE. 
To determine the effect of 13-HODE on the PAF- and fMLP- 
induced expression of CD1 lb  and CD67, PMNs were preincu- 
bated for 5 rain with 13-HODE whereafter PAF or fMLP was 
added. After pretreatment with 13-HODE, the PAF-induced 
upregulation of CDI lb  was significantly inhibited with 
24 + 7% (Fig. 2). 13-HODE also inhibited the PAF-induced 
increase of the expression of CD67 with 14 + 8%. In contrast, 
preincubation of PMNs with 13-HODE enhanced the upregu- 
Table 1 
Increase of expression of the degranulation markers CD 11 b and CD67 
on the plasma membrane of PMNs 
CD 11 b CD67 
13-HODE 125 + 29* 45 + 5* 
PAF 337 + 34* 124 + 23* 
fMLP 281 + 31" 135 + 20* 
PMNs (5 x 105/ml) were incubated with 13-HODE (5 pM), PAF (100 
nM) or fMLP (100 nM). Results are expressed as AMFI + S.E.M. of 
experiments performed with PMNs isolated from eight (CD 11 b) or five 
(CD67) different donors; *P < 0.05 compared to non-stimulated cells 
(MFI -- 311 _+ 36 MFI for CDI lb and 105 _+ 19 MFI for CD67 expres- 
sion). 
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Fig. 1. Flow cytometry analysis of the basal and 13-HODE (5 ,uM) 
induced expression of CD1 lb (A) and CD67 (B) on the plasma mem- 
brane of PMNs (5 x 105/ml). Representative histograms of eight (A) or 
five (B) experiments are shown, indicating basal expression (thin line) 
and 13-HODE-induced expression (thick line). 
lation of CDl lb  induced by fMLP with 29 _+ 8% (Fig. 2). The 
fMLP- induced expression of CD67 was increased with 
69 _+ 11% from 240 + 26 MF I  to 332 _+ 42 MF I  in PMNs prein- 
cubated with 13-HODE. 
4. Discussion 
In the present study it is demonstrated that the linoleic acid 
metabolite 13-HODE induced degranulat ion of human PMNs. 
This degranulat ion was detected by measuring the expression 
of CD1 lb, which is a marker for degranulation of secretory 
vesicles, tertiary and specific granules and CD67, which is a 
marker for specific granules, on the plasma membrane. 13- 
HODE (5/aM) upregulated both degranulat ion markers to the 
same extent. It is highly unlikely that small contaminat ions of
9 -HODE or 13-HPODE in our 13-HODE preparation were 
responsible for the observed effects, since 9-HODE nor 13- 
HPODE have been reported to be more potent han 13-HODE 
on different leukocyte functions [17,18]. Similar to 13-HODE, 
the arachidonic acid metabolites 5-HETE, 5-OxoETE and 
LTB4 have been reported to stimulate PMN degranulat ion [11]. 
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Regarding the concentration i which 13-HODE was used, 
5-HETE induced PMN degranulation at similar concentra- 
tions, i.e. I 10#M [21,22]. In addition, 13-HODE can be pro- 
duced in concentrations of up to 1 #M under non-stimulated 
conditions [20]. These data indicate that our present effects of 
13-HODE, observed at a 5-#M concentration, may be of phys- 
iological significance. 
The precise mechanism by which PMN degranulation is ac- 
complished is not completely understood. An elevation of the 
intracellular calcium concentration ([Ca>]0 is generally consid- 
ered to be important for degranulation [23]. However, 13- 
HODE induced PMN degranulation without a detectabe rise 
of [Ca>]~ [24]. Other investigators also observed PMN degran- 
ulation without an increase of [Ca>]i [9]. Activation of protein 
kinase C (PKCt with the phorbol ester PMA induces PMN 
degranulation without a change in cytosolic Ca > [25]. Unsatu- 
rated fatty acids, including arachidonic and linoleic acid, can 
stimulate PKC and induce PMN degranulation [26,27]. It is 
conceivable that also 13-HODE induces degranulation of 
PMNs by activation of PKC. Several other studies uggest a
modulatory role for [Ca:+]i and the involvement of additional 
signalling pathways in the degranulatory process. Thus, Nube 
et al. reported the involvement of GTP-binding proteins in 
addition to a pronounced effect of Ca "-+ on the dynamics of 
degranulation [28]. In permeabilized PMN preparations, 
GTPyS induced egranulation f azurophilic granules. Subse- 
quent addition of Ca > augmented the GTPyS-induced degran- 
ulation [29]. Fatty acids, such as arachidonic acid and its metab- 
olite 15-H ETE, have been shown to interact with GTP-binding 
proteins [13,30]. We cannot exclude that 13-HODE exerts its 
degranulatory esponse by interaction with GTP-binding pro- 
teins. 
In addition to its direct degranulatory activity a modulatory 
effect of 13-HODE on the PAF- and fMLP-induced egranula- 
tion was observed. 13-HODE attenuated the degranulatory 
response of PMNs to PAF. Previously, we observed a strong 
inhibitory effect of 13-HODE on the PAF-induced [Ca-'+]i-in - 
crease [24]. Since [Ca>]i can modulate PMN degranulation, the 
decrease of PAF-induced egranulation caused by 13-HODE 
may result from the inhibitory effect of 13-HODE on the PAF- 
induced [Ca2+]i. This explanation is supported by the observa- 
tion that the inhibitory effect of 15-HETE on the PAF-induced 
degranulation of PMNs coincides with a decreased rise of 
[Ca>]i [13]. The degranulatory response of PMNs to IMLP was 
additive on the 13-HODE-induced degranulation. In accord- 
ance, 13-HODE does not affect the fMLP-induced [Cae+]i-in - 
crease [24]. 
Expression of CDI l b on the cell surface is not only indicative 
for PMN degranulation, but also subserves PMN adhesion to 
other cells. CDl l  b belongs to the integrin family of adhesion 
molecules and is involved in the adherence of PMNs to acti- 
vated endothelial and epithelial cells by interaction with its 
counterstructure ICAM-I present on these cells [31,32]. Fol- 
lowing adhesion, PMNs transmigrate between the cells and 
migrate ahmg a gradient of chemoattractant, such as PAF and 
fMLP. to the inflammatory region. We previously observed 
chemotactic activity of 13-HODE towards PMNs in vitro [18]. 
The effects of 13-HODE on the upregulation of CDl lb  also 
suggest an important role for 13-HODE in the recruitment of
PMNs from the blood stream into the inflamed tissue. The 
possible role for 13-HODE in cell-cell interaction is supported 
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Fig. 2. Effect of 13-HODE (5 #M; black bars) on the basal, PAF (100 
nM) and tM LP (100 nM) induced expression ofCDII b (A) and CD67 
(B) on the plasma membrane of PMNs. Results are expressed as 
MF1 + S.E.M. of experiments performed with PMNs isolated fiom 
eight (A) or fixe (B) different donors: *P < 0.05. 
by a number of other studies. Buchanan et al. observed a 
decreased adhesion between PMNs and endothelial cells alter 
inhibition of 13-HODE synthesis in PMNs and endothelial 
cells, indicating a proadhesive role l\~r 13-HODE towards 
PMNs [33]. In contrast, 13-HODE inhibited PMA-induced ex- 
pression of the adhesion molecule Gpllb/l l la on tumor cells 
[34]. Furthermore, it has been found that a decrease of the 
intracellular 13-HODE levels in endothelial cells corresponds 
with an enhanced expression of the vitronectin receptor and an 
increase of endothelial cell adhesivity [35]. 
In conclusion, results of the present study indicate that the 
linoleic acid metabolite 13-HODE, produced and released by 
several inflammatory cells including PMNs, induces and modu- 
lates PMN degranulation. Moreover. the effect o[" 13-HODE 
on the expression of the adhesion molecule CDII b, suggests a 
modulatory role for 13-HODE in the interaction of PMNs to 
other cell types. 
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